Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One ultra-mutated GBM had microsatellite instability (MSI), a somatic MSH6 mutation, and a germline POLE mutation.
|
31480372 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme.
|
30867843 |
2019 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that increased expression of MSH6, or other MMR, may be a new mechanism contributing to the acquired resistance during TMZ therapy; and may serve as an indicator to the resistance in GBM.
|
29366782 |
2018 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High TML was only found in 3.5% of GBM patients (7 of 198) and was associated with the absence of protein expression of mutL homolog 1 (MLH1) (P = .0345), mutS homolog 2 (MSH2) (P = .0099), MSH6 (P = .0022), and postmeiotic segregation increased 2 (PMS2) (P = .0345) and the presence of DNA MMR mutations.
|
28371827 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that both glioblastomas had 2 hits in the MSH6 gene, and that loss of MSH6 function was the key event in the pathogenesis of these 2 independent primary glioblastomas.
|
28922847 |
2017 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Formerly, we found evidence of prognostic impact of MLH1 and MSH6 immunohistochemical expression in a small series of patients with initial glioblastoma.
|
24995467 |
2015 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
|
25078279 |
2014 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma.
|
23057844 |
2013 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated whether glioblastoma recurrence is associated with changes in the promoter methylation status and the expression of MGMT and the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 in pairs of primary and recurrent glioblastomas of 80 patients, including 64 patients treated with radiotherapy and TMZ after the first operation.
|
21425258 |
2011 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report a case with CMMR-D caused by novel homozygous MSH6 mutations leading to gliomatosis cerebri and T-ALL in an 11-year-old female and glioblastoma multiforme in her 10-year-old brother, both with rapid progression of the diseases.
|
21674763 |
2011 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific attention should be given on the role of MLH1 and MSH6 in patients with glioblastoma recurrence during temozolomide treatment.
|
20223108 |
2010 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In vitro modeling through exposure of an MSH6 wild-type glioblastoma line to temozolomide resulted in resistant clones; one clone showed an MSH6 mutation, Thr(1219)Ile, that had been independently noted in two treated TCGA glioblastomas.
|
19584161 |
2009 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MSH6 mutation was not observed in any pretreatment glioblastoma (0 of 40), whereas 3 of 14 recurrent cases had somatic mutations (P = 0.015).
|
17404084 |
2007 |